Bone Biologics (BBLG) Stock Price, News & Analysis

Company Overview

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.

Key Stats

• Today's Range: $1.00 to $1.04
• 50-Day Range: $0.90 to $1.27
• 52-Week Range: $0.80 to $4.49
• Volume: 98,082 shs
• Average Volume: 286,097 shs
• Market Capitalization: $2.51 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Bone Biologics Stock Analysis - MarketRank™

Bone Biologics scored higher than 5% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Bone Biologics.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Bone Biologics are expected to grow in the coming year, from ($5.00) to ($1.95) per share.

Price to Book Value per Share Ratio

Bone Biologics has a P/B Ratio of 0.14. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

29.06% of the float of Bone Biologics has been sold short.

Short Interest Ratio / Days to Cover

Bone Biologics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bone Biologics has recently increased by 105.03%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Bone Biologics does not currently pay a dividend.

Dividend Growth

Bone Biologics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

29.06% of the float of Bone Biologics has been sold short.

Short Interest Ratio / Days to Cover

Bone Biologics has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bone Biologics has recently increased by 105.03%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Bone Biologics this week, compared to 0 articles on an average week.

MarketBeat Follows

1 people have added Bone Biologics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Bone Biologics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.50% of the stock of Bone Biologics is held by insiders.

Percentage Held by Institutions

Only 34.30% of the stock of Bone Biologics is held by institutions.

BBLG Stock Analysis - Frequently Asked Questions

How have BBLG shares performed this year?

Bone Biologics' stock was trading at $0.9403 at the beginning of the year. Since then, BBLG shares have increased by 7.4% and is now trading at $1.01.
View the best growth stocks for 2025 here.

How were Bone Biologics' earnings last quarter?

Bone Biologics Co. (NASDAQ:BBLG) released its quarterly earnings results on Friday, August, 9th. The company reported ($0.67) EPS for the quarter, beating analysts' consensus estimates of ($1.39) by $0.72.

When did Bone Biologics' stock split?

Shares of Bone Biologics reverse split on Wednesday, December 20th 2023. The 1-8 reverse split was announced on Wednesday, December 20th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, December 20th 2023. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

When did Bone Biologics IPO?

Bone Biologics (BBLG) raised $8 million in an initial public offering on Wednesday, October 13th 2021. The company issued 1,510,455 shares at $5.25 per share.

How do I buy shares of Bone Biologics?

Shares of BBLG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Bone Biologics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Bone Biologics investors own include Broadcom (AVGO), NVIDIA (NVDA), Annovis Bio (ANVS), CrowdStrike (CRWD), Dell Technologies (DELL), FedEx (FDX) and Meta Platforms (META).

Company Calendar

• Last Earnings: 8/09/2024
• Today: 2/22/2025
• Next Earnings (Estimated): 5/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical appliances & supplies
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:BBLG
• Previous Symbol: NASDAQ:BBLG
• CUSIP: N/A
• CIK: 1419554
• Web: www.bonebiologics.com
• Phone: 781-552-4452
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-8,950,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -124.71%
• Return on Assets: -111.64%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 14.89
• Quick Ratio: 14.89

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.42 per share
• Price / Book: 0.14

Miscellaneous

• Outstanding Shares: 2,490,000
• Free Float: 2,306,000
• Market Cap: $2.51 million
• Optionable: Not Optionable
• Beta: 0.55